Curia signs license agreement with MilliporeSigma to support production of proteins and antibodiesALBANY, N.Y., June 20, 2023 (GLOBE NEWSWIRE) -- Curia, a leading contract research, development ...

Mammalian HCP ELISA Kits represent a useful technology in biopharmaceutical quality control processes. They can detect and quantify residual host cell proteins that may contaminate biological products ...

Discover how to streamline your cell line development process for recombinant protein and monoclonal antibody production with this in-depth eBook. Whether you're working with CHO, HEK293, or ...

AMERSHAM, England, Oct. 6, 2022 /CNW/ -- Global life sciences leader Cytiva has acquired CEVEC Pharmaceuticals, a leading German provider of high-performance cell line development and viral vector ...

These innovations are not only shaping the future of cell-based therapies but are also crucial for the next generation of complex biologics. Continue reading this article to explore the latest ...

Successfully producing large quantities of biotherapeutics, including monoclonal antibodies and recombinant protein products, depends on robust and reliable cell line development (CLD). Issues ...

Insourcing cell-line development has helped a fast-growing antibody manufacturer to deliver process improvements and strengthen communication with their contract manufacturer, according to Genmab ...

The cell line development market size is expected to experience a 10.3% CAGR from 2024 to 2032, driven by an increase in product innovations and technological advancements.Biotech companies and ...

The cell line development market is growing at a CAGR of approximately 8-10% due to the increasing adoption of cell-based therapies. Key drivers include the rising demand for monoclonal antibodies, ...

ALBANY, N.Y., June 20, 2023 (GLOBE NEWSWIRE) — Curia, a leading contract research, development and manufacturing organization, today announced it has signed a licensing agreement with MilliporeSigma, ...